.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

LIPITOR Drug Profile

« Back to Dashboard
Lipitor is a drug marketed by Pfizer and is included in one NDA. It is available from eleven suppliers. There is one patent protecting this drug.

This drug has sixty-four patent family members in thirty-six countries.

The generic ingredient in LIPITOR is atorvastatin calcium. There are sixty drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the atorvastatin calcium profile page.

Summary for Tradename: LIPITOR

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list11

Pharmacology for Tradename: LIPITOR

Clinical Trials for: LIPITOR

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer
LIPITOR
atorvastatin calcium
TABLET;ORAL020702-001Dec 17, 1996RXNo5,969,156*PED<disabled>Y<disabled>
Pfizer
LIPITOR
atorvastatin calcium
TABLET;ORAL020702-004Apr 7, 2000RXYes5,969,156*PED<disabled>Y<disabled>
Pfizer
LIPITOR
atorvastatin calcium
TABLET;ORAL020702-002Dec 17, 1996RXNo5,969,156*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: LIPITOR

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer
LIPITOR
atorvastatin calcium
TABLET;ORAL020702-003Dec 17, 19964,681,893*PED<disabled>
Pfizer
LIPITOR
atorvastatin calcium
TABLET;ORAL020702-001Dec 17, 19965,686,104*PED<disabled>
Pfizer
LIPITOR
atorvastatin calcium
TABLET;ORAL020702-002Dec 17, 1996RE40667*PED<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: LIPITOR

Country Document Number Estimated Expiration
Poland324496<disabled in preview>
Slovakia6298<disabled in preview>
Slovenia1148049<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: LIPITOR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
545Luxembourg<disabled>PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ATORVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ATORVASTATINE SOUS FORME D'ATORVASTATINE CALCIQUE TRIHYDRATEE; FIRST REGISTRATION: 20140910
2014 00050Denmark<disabled>PRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910
C0048France<disabled>PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc